S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Modern Day Options Trading For Beginners! (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Modern Day Options Trading For Beginners! (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Did You See These Trend Reversals? (Ad)pixel
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Modern Day Options Trading For Beginners! (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Modern Day Options Trading For Beginners! (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Did You See These Trend Reversals? (Ad)pixel
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Modern Day Options Trading For Beginners! (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Modern Day Options Trading For Beginners! (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Did You See These Trend Reversals? (Ad)pixel
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Modern Day Options Trading For Beginners! (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Modern Day Options Trading For Beginners! (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Did You See These Trend Reversals? (Ad)pixel
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
NYSE:ABBV

AbbVie - ABBV Stock Forecast, Price & News

$159.37
+1.45 (+0.92%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$157.73
▼
$159.57
50-Day Range
$144.61
▼
$159.37
52-Week Range
$134.09
▼
$175.91
Volume
4.96 million shs
Average Volume
7.00 million shs
Market Capitalization
$281.15 billion
P/E Ratio
24.11
Dividend Yield
3.71%
Price Target
$161.12

AbbVie MarketRank™ Forecast

Analyst Rating
Hold
2.44 Rating Score
Upside/​Downside
1.1% Upside
$161.12 Price Target
Short Interest
Healthy
0.80% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.34
Upright™ Environmental Score
News Sentiment
0.52mentions of AbbVie in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$24.27 M Sold Last Quarter
Proj. Earnings Growth
0.27%
From $10.97 to $11.00 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.54 out of 5 stars

Medical Sector

135th out of 1,004 stocks

Pharmaceutical Preparations Industry

53rd out of 489 stocks

See Top Rated MarketRank™ Stocks Here

ABBV stock logo

About AbbVie (NYSE:ABBV) Stock

AbbVie Inc. is a US-based biopharma company with global operations. The company originated as the bio-pharma segment of Abbott Laboratories and was spun off in late 2012. The company officially IPOd on January 2, 2013; contrary to criticisms, the move was solely to protect the parent company from expiring patents. Post-spin, AbbVie emerged as a research-based biopharma that has more than doubled in size. AbbVie, like its parent Abbot Laboratories, is a well-established dividend growth stock.

Over the years, AbbView Inc. has made numerous acquisitions. Among the more notable are ImmuVen, Pharamcyclics and Allergan plc. Allergan plc was an Ireland-based pharmaceutical company focused on health-oriented aesthetic products and is the owner of Botox. Botox accounts for the bulk of the company’s Aesthetics portfolio revenue and about 4% of the net as of 2022. The total revenue in 2021 was $56.20 billion with a 31% operating margin.

Today, AbbVie operates as a diversified multi-national pharmaceutical company with a patient-centric approach to research. It is in business to discover, develop, manufacture and market pharmaceuticals globally but in a way that best serves the needs of patients and the global community.

The company’s original winner, Humira, is still the number one revenue source but the portfolio has been greatly expanded. Other profitable therapies include but are not limited to SKYRIZI for psoriasis, RINVOQ for rheumatoid arthritis and IMBRUVICA and VENCLEXTA for chronic leukemia conditions.

The company is focused on research and has a number of collaborations and partnerships to that end. Among the many avenues of research and innovation are the advancement of precision medicine or pMedicine. PMeds are designed not only to target the specific causes of diseases, often at the genetic level, but the patients that are most likely to benefit from them. Assuming there are 2 highly effective drugs for 1 disease, PMedicine seeks to identify which patients respond better to each.

As of 2022, AbbVie employed more than 50,000 people globally with 21,000 in STEM-related positions. To date, the company had invested more than $50 billion into research through more than 250 partnerships. Partnerships are with universities, medical facilities, research organizations and other pharmaceutical companies. The company’s operations span 20 countries, treating more than 60 million people and 40 conditions annually.

AbbVie has 5 focus areas for its research and products. These are Immunology, Oncology, Neurology, Virology and Eye Care. The company has a robust pipeline of new products that are in some stage of clinical trials. In most cases, trials are underway for multiple indications, including some therapies that have already been approved for 1 or more conditions.

AbbVie is a leader in ESG and sustainability. The company is a member of the Fortune 100 and one of the Fortune 100’s “Best Companies To Work For”. It is a Top 50 Company regarding diversification and a member of the Dow Jones Sustainability World Index and the S&P ESG Index. Among its many positions is sustainable operations so it can deliver life-changing therapies to those who need them most.

Receive ABBV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.

ABBV Stock News Headlines

March 27, 2023 | marketbeat.com
BioNTech Is Ripe For A Rebound In 2023  (ABBV)
BioNTech had a strong quarter and may become a takeover target due to its healthy pipeline and a looming patent cliff for big pharma.
March 22, 2023 | marketbeat.com
These 3 Dividend Growers Yield More Than the 10-Year Note (ABBV)
Dividend aristocrats with yields greater than the 10-year note yield plus the potential for price appreciation could be a winning formula in this environment.
April 1, 2023 | Vantage Point (Ad)
The Market Crash Shield is A.I.
Are you using the best technology to dominate April markets? This A.I. has traders doubting their methods. Attend This Live (FREE) A.I. Market Training. pixel
March 14, 2023 | marketbeat.com
Healthcare Stocks With at Least 30 Years of Dividend Increases (ABBV)
Among the many industry sectors to invest in, healthcare can be one of the most stable, especially regarding the dividend yield.
March 14, 2023 | marketbeat.com
Diversify Your Income with These 2 High-Yielding Dividend ETFs (ABBV)
Diversification is a term widely used when it comes to investing in the stock market. It means spreading your investment across different sectors and indust
March 7, 2023 | marketbeat.com
How to Pick the Best Dividend Stocks (ABBV)
A stock’s dividend yield is a key metric for investors, so what is a good dividend yield? We’ll explore the answer in this article.
March 7, 2023 | marketbeat.com
The Stock That Tripled in a Day...And May Not Be Done (ABBV)
Reata Pharmaceuticals now has a long-coveted commercialized drug in its portfolio. Should investors covet this biotech stock for their portfolios?
March 2, 2023 | dividendstocks.com
AbbVie Stock: ABBV Overview and Dividend Potential
April 1, 2023 | Investorplace Media (Ad)
5 Hypergrowth Stocks to Buy Now
Luke Lango has found 14 stocks that have gone up over 1,000%. Now he’s named his top stocks for 2023. Just click to claim your copy. pixel
March 2, 2023 | marketbeat.com
Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor (ABBV)
Revance Therapeutics gapped up 54.34% on January 9, and built upon those gains in February. The company reported its first revenue for Botox competitor Daxxify.
April 1, 2023 | finance.yahoo.com
AbbVie Inc. (NYSE:ABBV) insiders sold US$6.3m worth of stock, possibly signalling a downtrend
April 1, 2023 | finance.yahoo.com
Could This Drug News Lift AbbVie's Stock?
March 31, 2023 | fool.com
This Blockbuster Drug's Latest News Could Be Another Home Run for AbbVie
March 29, 2023 | finance.yahoo.com
Better Growth Stock: Vertex Pharmaceuticals vs. AbbVie
March 28, 2023 | finance.yahoo.com
AbbVie Walks Away From CytomX Partnership, But Garnering Attention Of Big Pharma Partners
March 28, 2023 | seekingalpha.com
CytomX slumps ~15% amid FY22 miss, AbbVie pulls plug on CX-2029 studies
March 27, 2023 | finance.yahoo.com
The Zacks Analyst Blog Highlights Sanofi, Regeneron, AbbVie, Roche and Eli Lilly
March 27, 2023 | finance.yahoo.com
Here's Why AbbVie (NYSE:ABBV) Can Manage Its Debt Responsibly
March 23, 2023 | finance.yahoo.com
The price of Humira's biosimilars can uncloak the secret villain of US drug pricing
March 23, 2023 | finance.yahoo.com
Use These 3 Strategies to Make $1,000 in Passive Income Per Year
March 23, 2023 | finance.yahoo.com
AbbVie (NYSE:ABBV) shareholders have earned a 37% CAGR over the last three years
March 23, 2023 | fool.com
2 Reasons to Buy AbbVie, and 1 Reason to Sell
March 22, 2023 | benzinga.com
AbbVie Provides Regulatory Update On Parkinson's Disease Drug Candidate
March 22, 2023 | finance.yahoo.com
AbbVie Provides Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) New Drug Application
March 22, 2023 | finance.yahoo.com
UPDATE 1-US FDA declines to approve AbbVie's Parkinson's disease therapy
March 22, 2023 | seekingalpha.com
AbbVie lower as FDA rejects Parkinson's therapy
March 21, 2023 | stocknews.com
2 Top Stocks That Should Be on Your Radar This Spring
See More Headlines
Receive ABBV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.

ABBV Company Calendar

Ex-Dividend for 2/15 Dividend
1/12/2023
Last Earnings
2/09/2023
Dividend Payable
2/15/2023
Today
4/01/2023
Ex-Dividend for 5/15 Dividend
4/13/2023
Next Earnings (Estimated)
5/05/2023
Dividend Payable
5/15/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NYSE:ABBV
CUSIP
00287Y10
CIK
1551152
Web
www.abbvie.com
Phone
(847) 932-7900
Fax
302-655-5049
Employees
50,000
Year Founded
2013

Price Target and Rating

Average Stock Price Forecast
$161.12
High Stock Price Forecast
$200.00
Low Stock Price Forecast
$140.00
Forecasted Upside/Downside
+1.1%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
16 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$6.61
Trailing P/E Ratio
24.11
Forward P/E Ratio
14.53
P/E Growth
3.6
Net Income
$11.84 billion
Net Margins
20.39%
Pretax Margin
23.22%
Return on Equity
154.52%
Return on Assets
17.54%

Debt

Debt-to-Equity Ratio
3.42
Current Ratio
0.96
Quick Ratio
0.84

Sales & Book Value

Annual Sales
$58.05 billion
Price / Sales
4.84
Cash Flow
$18.86 per share
Price / Cash Flow
8.45
Book Value
$9.78 per share
Price / Book
16.30

Miscellaneous

Outstanding Shares
1,764,140,000
Free Float
1,762,731,000
Market Cap
$281.15 billion
Optionable
Optionable
Beta
0.62

Social Links


Key Executives

  • Richard A. GonzalezRichard A. Gonzalez
    Chairman & Chief Executive Officer
  • Robert A. MichaelRobert A. Michael
    Vice Chairman & President
  • Azita Saleki-GerhardtAzita Saleki-Gerhardt
    Executive Vice President-Operations
  • Scott T. ReentsScott T. Reents
    Chief Financial Officer & Executive Vice President
  • Thomas J. Hudson
    Chief Scientific Officer, Senior VP-R&D

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ABBV Stock - Frequently Asked Questions

Should I buy or sell AbbVie stock right now?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 9 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ABBV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABBV, but not buy additional shares or sell existing shares.
View ABBV analyst ratings or view top-rated stocks.

What is AbbVie's stock price forecast for 2023?

16 analysts have issued twelve-month price objectives for AbbVie's shares. Their ABBV share price forecasts range from $140.00 to $200.00. On average, they anticipate the company's stock price to reach $161.12 in the next year. This suggests a possible upside of 1.1% from the stock's current price.
View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts.

How have ABBV shares performed in 2023?

AbbVie's stock was trading at $161.61 on January 1st, 2023. Since then, ABBV stock has decreased by 1.4% and is now trading at $159.37.
View the best growth stocks for 2023 here.

Are investors shorting AbbVie?

AbbVie saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 12,700,000 shares, an increase of 8.5% from the February 13th total of 11,710,000 shares. Based on an average daily volume of 5,620,000 shares, the days-to-cover ratio is presently 2.3 days.
View AbbVie's Short Interest.

When is AbbVie's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023.
View our ABBV earnings forecast.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) announced its quarterly earnings data on Thursday, February, 9th. The company reported $3.60 EPS for the quarter, beating analysts' consensus estimates of $3.54 by $0.06. The firm had revenue of $15.12 billion for the quarter, compared to analysts' expectations of $15.30 billion. AbbVie had a trailing twelve-month return on equity of 154.52% and a net margin of 20.39%. The company's revenue for the quarter was up 1.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.31 EPS.
Read the conference call transcript.

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie declared a quarterly dividend on Thursday, February 16th. Investors of record on Friday, April 14th will be paid a dividend of $1.48 per share on Monday, May 15th. This represents a $5.92 annualized dividend and a yield of 3.71%. The ex-dividend date of this dividend is Thursday, April 13th.
Read our dividend analysis for ABBV.

What ETFs hold AbbVie's stock?

ETFs with the largest weight of AbbVie (NYSE:ABBV) stock in their portfolio include First Trust Morningstar Dividend Leaders Index (FDL), iShares Core High Dividend ETF (HDV), Invesco Dynamic Pharmaceuticals ETF (PJP), Health Care Select Sector SPDR Fund (XLV), VanEck Pharmaceutical ETF (PPH), Sound Equity Income ETF (SDEI), Kelly CRISPR & Gene Editing Technology ETF (XDNA) and iShares U.S. Healthcare ETF (IYH).

Is AbbVie a good dividend stock?

AbbVie (NYSE:ABBV) pays an annual dividend of $5.92 per share and currently has a dividend yield of 3.75%. The company has been increasing its dividend for 51 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 89.56%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ABBV will have a dividend payout ratio of 53.82% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ABBV.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie updated its FY 2024 earnings guidance on Friday, February, 10th. The company provided EPS guidance of $10.70- for the period. The company issued revenue guidance of -.

What is Richard A. Gonzalez's approval rating as AbbVie's CEO?

580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among the company's employees.

What other stocks do shareholders of AbbVie own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), AT&T (T), Bristol-Myers Squibb (BMY), Wheaton Precious Metals (WPM), Rogers Communications (RCI) and Open Text (OTEX).

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

How do I buy shares of AbbVie?

Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $159.37.

How much money does AbbVie make?

AbbVie (NYSE:ABBV) has a market capitalization of $281.15 billion and generates $58.05 billion in revenue each year. The company earns $11.84 billion in net income (profit) each year or $6.61 on an earnings per share basis.

How many employees does AbbVie have?

The company employs 50,000 workers across the globe.

Does AbbVie have any subsidiaries?
The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska družba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacéuticos S.A. de C.V., AbbVie Farmacêutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S.à r.l., AbbVie Investments Limited, AbbVie Investments S.à r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementär GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. Ltd., AbbVie Overseas S.à r.l., AbbVie Oy, AbbVie Participações Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. z o.o., AbbVie Productos Farmacéuticos Limitada, AbbVie Products LLC, AbbVie Promoção L.da, AbbVie Pte. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S.à r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Bhd., AbbVie Sp. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tıbbi İlaçlar Sanayi ve Ticaret Limited Şirketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundación AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC.
Read More
How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The official website for the company is www.abbvie.com. The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049.

This page (NYSE:ABBV) was last updated on 4/1/2023 by MarketBeat.com Staff